Avagenesis Corp. Appoints Distributor for Brazil
Friday, 17 August 2018 05:40 PM
Avagenesis Corp. (“Avagenesis” or the “Company”) (TSXV: VVA), is pleased to announce the appointment of a non-exclusive distributor of the Avagenesis System for the Federative Republic of Brazil (“Brazil”).
“Brazil is one of the largest cosmetic surgery markets in the world,” stated Norman Tsui, Chief Executive Officer of Avagenesis. “We are well positioned to strategically launch into new markets that provide excellent growth prospects.”
Brazil represents the 2nd largest market globally for overall cosmetic procedures according to the most recent survey published by the International Society of Aesthetic Plastic Surgeons (ISAPS).
About Avagenesis Corp.
Avagenesis is a biotechnology company engaged in the commercialization of licensed cell isolation medical technologies for use in regenerative medical aesthetics. Patent registrations, FDA registrations and other regulatory certificates are arranged through an exclusive licensing agreement with a related and affiliated company.
Neither the Exchange nor its regulation services provider (as that term is defined in the policies of the Exchange) accepts responsibility for the adequacy or accuracy of this press release.
Cautionary Statements
Certain statements contained in this press release constitute forward-looking information. These statements relate to future events or future performance. The use of any of the words "could", "intend", "expect", "believe", "will", "projected", “likely”, "estimated" and similar expressions and statements relating to matters that are not historical facts are intended to identify forward-looking information and are based on Avagenesis' current belief or assumptions as to the outcome and timing of such future events. Actual future results and developments may differ materially from those contemplated by these statements depending on, among other things, the risk that Avagenesis may not successfully transition to a clinical stage company and the risk that Avagenesis may not successfully execute its development and commercialization activities. Various assumptions or factors are typically applied in drawing conclusions or making the forecasts or projections set out in forward-looking information. Those assumptions and factors are based on information currently available to Avagenesis. Avagenesis cautions the reader that the above list of risk factors is not exhaustive. The forward-looking information contained in this press release is made as of the date hereof and Avagenesis is not obligated to update or revise any forward-looking information, whether as a result of new information, future events or otherwise, except as required by applicable securities laws. Because of the risks, uncertainties and assumptions contained herein, investors should not place undue reliance on forward-looking information. The foregoing statements expressly qualify any forward-looking information contained herein.
Further Information
For further information, please contact:
Avagenesis Corp.
Alan Tam, CPA, CA
Chief Financial Officer
Telephone: (604) 377-7575
